Patent Grant
10420644
The present disclosure relates to medical devices for treating heart diseases and valvular dysfunction, including valvular regurgitation.
Various compression-style systems currently exist for treating heart diseases and conditions such as congestive heart disease and valvular dysfunction. These systems typically involve either: (a) jackets that are placed around the heart to limit heart expansion to treat congestive heart disease, or (b) bands that are placed around the heart with fillable chambers to exert localized pressure to re-form the shape of heart valves, for example to minimize valve leakage.
An example of the former is found in U.S. Published Patent Application 2010/0160721 entitled “Cardiac Support Device With Differential Compliance.” This device is used to treat congestive heart disease. Congestive heart disease is the progressive enlargement of the heart. This enlargement requires the heart to perform an increasing amount of work. In time, the heart cannot supply an adequate amount of blood, resulting in a patient that is fatigued and in discomfort. The cardiac support device of U.S. Application 2101/0160721 limits heart expansion using a flexible jacket positioned around the heart. An example of the second type of system is found in Mardil, Inc.'s U.S. Pat. No. 8,092,363 entitled “Heart Band With Fillable Chambers To Modify Heart Valve Function.” This device has fillable chambers that exert inward radial forces on heart valves. The fillable chambers are disposed within inner and outer layers of a silicone rubber band.
Some embodiments described herein provide a system including an cardiac implant structure configured to be positioned around the exterior of an epicardial surface of a heart. Such a system can be used, for example, to treat various heart conditions, including but not limited to functional mitral regurgitation (“FMR”), tricuspid valve regurgitation, congestive heart failure, or a combination thereof. The implant structure can include a mesh body having a leading hem region configured to elastically flex and engage with an atrial-ventricular groove of the heart, and a fillable bladder mounted to the mesh body at a predetermined location so as to provide localized pressure at a targeted surface region of the heart spaced apart from the atrial-ventricular groove. The implant structure can be equipped with radiopaque markers at selected locations along the leading hem region, along or within the fillable bladder, or a combination thereof, so that the relative positioning of the implant structure and the targeted landmarks of the heart can be readily identified both during and after an implantation procedure. For example, in particular embodiments, the fillable bladder (equipped with markers along a periphery thereof) can be coupled to the mesh body at a specific location to exert a localized pressure on the posterior lateral surface of the heart to thereby deflect the “P2” portion of the posterior leaflet of the mitral valve to treat FMR. Accordingly, the combined components of the implant structure can be configured to apply supporting or deformation forces to multiple targeted regions of the heart in a manner that supports the ventricle walls of the heart, particular valve structures of the heart, and (optionally) the atrial-ventricular groove of the heart.
Additionally, some embodiments of a method for delivering the implant structure to the heart can be achieved in a minimally invasive manner that benefits both the clinician and the user. A delivery device can be operated by a surgeon or other clinician to advance the implant structure through a relatively small opening of a selected intercostal space before the implant structure expands over the apex, ventricles, and atrial-ventricular groove of the heart. In a particular embodiment, the implant structure can be pre-loaded on the delivery device and packaged in a sterilized kit so that the clinician can advantageously begin the implantation procedure without first having to load the implant device onto the delivery device. Also, the implant structure may optionally be loaded onto the delivery device in a predetermined relative position so that the fillable bladder has a predetermined orientation relative to a handle of the delivery device, thereby assisting the clinician in aligning the fillable bladder with the targeted surface region of the heart (e.g., along a posterior lateral surface of the heart in particular implementations). In some implementations of the method, the fillable bladder (when inflated) of the implant structure can be configured to expand inwardly toward the epicardial surface more so than it expands outwardly away from the heart.
Particular embodiments described herein include a cardiac implant including an implant body and a fillable bladder. The implant body can comprise a mesh material, and the implant body may include a leading end portion defining an open leading end and a trailing end portion defining an open trailing end of a diameter that is less than a diameter of the open leading end. The fillable bladder can be coupled to the implant body. Optionally, the cardiac implant may include one or more additional features described in more detail below.
Particular embodiments described herein include a cardiac implant for implantation around an exterior of a heart. The implant may include an implant body comprising a mesh material, which optionally is formed into a generally tubular configuration. The implant body may also include a leading end portion defining an open leading end and a trailing end portion defining an open trailing end of a diameter that is less than a diameter of the open leading end. The trailing end portion may have a length configured to extend proximal of the apex of the heart when the leading end portion is positioned in an atrial-ventricular groove of the heart. Further, the cardiac implant may optionally include a fillable bladder mounted to the implant body. The fillable bladder may be positioned relative to the open leading end such that, when the leading end portion is positioned in the atrial-ventricular groove, the fillable bladder is positionable on an exterior of a heart wall. Optionally, the cardiac implant may include one or more additional features described in detail herein.
In some embodiments, a cardiac implant for implantation around an exterior of a heart may include an implant body. The implant body can comprises a mesh material that, optionally, is formed into a generally tubular configuration. The implant body may define an open leading end and an open trailing end of a lateral width that is less than a lateral width of the open leading end. The implant body may include: a generally cylindrical leading end portion, a transition portion, and a generally cylindrical trailing end portion. The generally cylindrical leading end portion can define the open leading end of the implant body, and the leading end portion may have a lateral width and construction for positioning around an atrial-ventricular groove of the heart. The transition portion may extend proximally from the leading end portion and may be configured to circumferentially encompass ventricles of the heart. Optionally, the transition portion can have a greater diameter at its distal end than at its proximal end. The generally cylindrical trailing end portion may extend proximally from the transition portion and may have a length sized such that the trailing end portion extends proximal of the apex of the heart when the leading end portion is positioned around the atrial-ventricular groove. The cardiac implant may also include a fillable bladder coupled to the implant body. The fillable bladder can be positioned such that, when the leading end portion is positioned around the atrial-ventricular groove, the fillable bladder is positionable on an exterior of a heart wall adjacent to a heart valve structure. Optionally, the cardiac implant may further include one or more additional features described in detail herein.
In particular embodiments, a cardiac implant for implantation around an exterior of a heart can include an implant body comprising a jacket of mesh material configured for implantation circumferentially around ventricles of the heart. The jacket may an open leading end sized for positioning around an atrial-ventricular groove of the heart. The implant body may also include a hem located around a perimeter of the open leading end. The hem may be formed from a portion of the mesh material and an elastic band surrounded by the portion of the mesh material. Optionally, the circumferential length of the elastic band may be less than the circumferential length of the portion of the mesh material surrounding the elastic band. The elastic band and the portion of the mesh material surrounding the elastic band can have compliances selected such that the hem holds the hem of the implant body in place in the atrial-ventricular groove without interfering with cardiac blood vessel function in the region of the atrial-ventricular groove. Also, the cardiac implant may optionally include a fillable bladder attached on an inside of the mesh jacket. The fillable bladder may be positioned such that, when the implant is implanted with the hem positioned around the atrial-ventricular groove, the fillable bladder is positionable on an external heart wall adjacent to a targeted heart valve structure. The fillable bladder may include an inner layer and an opposing outer layer. The inner layer, when the hem positioned around the atrial-ventricular groove, can be adjacent to the external heart wall. The opposing outer layer may be adjacent to the mesh jacket. The inner layer of the fillable bladder can have a compliance that is greater than a compliance of the outer layer such that, when the bladder is inflated, the inner layer of the bladder extends more inwardly than the outer wall extends outwardly. Optionally, the cardiac implant may include one or more additional features described in detail herein.
Some embodiments described herein include a cardiac implant for implantation around an exterior of a heart. The cardiac implant may include a mesh jacket positionable circumferentially around an exterior the heart. Also, the cardiac implant may include a fillable bladder mounted to the mesh jacket. The fillable bladder can include an inner bladder layer and outer bladder layer. The inner bladder layer can be positioned with respect to the mesh jacket so that the inner bladder layer is adjacent to a targeted exterior surface of the heat when the mesh jacket is positioned around the exterior of the heart. The outer bladder layer can be positioned opposite from the inner bladder layer. Optionally, the inner bladder layer may have a compliance that is greater than a compliance of the outer bladder layer such that, when the mesh jacket is positioned around the exterior of the heart, the bladder expands more inwardly toward the targeted exterior surface of the heart than the bladder expands outwardly from the heart. Further, the cardiac implant may optionally include one or more additional features described in detail herein.
Further embodiments described herein include a cardiac implant system. The system may include a cardiac implant configured to be implanted around an exterior of the heart. The cardiac implant can include an implant body, an inflatable bladder attached to the implant body, and flexible tubing in fluid communication with an internal chamber of the inflatable bladder for inflating and deflating the inflatable bladder. The system may optionally include biocompatible ligation clips configured to attach to a proximal portion of the flexible tubing so as to seal an internal lumen of the flexible tubing. In some aspects, the ligation clips are configured to reside in an intercostal space while maintaining a selected inflation state of the inflatable bladder. Optionally, the cardiac implant system may include one or more additional features described in detail herein.
In various embodiments, a cardiac implant can include a mesh jacket, a fillable bladder, and one or more radiopaque markers. The mesh jacket may be configured to circumferentially extend around an exterior portion of the heart. The fillable bladder can be attached on an interior side of the mesh jacket. The fillable bladder may be positioned relative to a leading end of the mesh jacket such that, when the mesh jacket circumferentially extends around the exterior portion of the heart, the fillable bladder is positionable against an external heart wall adjacent to the a targeted valve structure. The fillable bladder may include an inner layer configured to engage with the external heart wall, and an outer layer positioned between the inner layer and the mesh jacket. The one or more radiopaque markers can be attached to an exterior side of the mesh jacket at a location wherein the fillable bladder is on an opposite side of the mesh jacket from the one or more radiopaque markers. Optionally, the cardiac implant may include one or more additional features described in detail herein.
Other embodiments described herein include a delivery system for delivering an implantable cardiac device. The delivery system may include an elongate barrel, a plurality of elongate members, a control mechanism, and a handle assembly. The plurality of elongate members may be configured to extend along a length of the elongate barrel and extend distally from the elongate barrel. Also, the plurality of elongate members may be advanceable distally with respect to the elongate barrel. Each of the elongate members can include a distal end for attachment to a cardiac implant configured to be implanted around an exterior of a heart. The control mechanism can be configured to extend and retract the plurality of elongate members relative to the elongate barrel. The handle assembly may optionally include a pistol grip configured to be held by a first hand of an operator while the operator uses a second hand to operate the control mechanism for the extension and retraction of the plurality of elongate members. Optionally, the delivery system may include one or more additional features described in detail herein.
Some embodiments described herein include a cardiac treatment system including a delivery system and a cardiac implant releasably mounted onto the delivery system. The delivery system may include an implant delivery mechanism comprising a plurality of distally extending elongate members each having a distal end portion configured for attachment to the cardiac implant. Also, the delivery system may include a proximal handle assembly. The proximal handle assembly can include a pistol grip configured to be held by one hand of an operator during a procedure to implant the cardiac implant. The pistol grip can extend in a first radial position from a longitudinal axis of the delivery system. The cardiac implant may include an implant body configured for implantation around external portions of a heart. The implant body can include a leading end portion defining an open leading end and being configured to advance over an apex of the heart. The leading end portion may be detachably attached to the distal end portions of the elongate members. The cardiac implant may also include a fillable bladder attached to the implant body. In particular implementations, the implant body may be mounted onto the delivery device in a second radial position from the longitudinal axis such that an orientation of the fillable bladder relative to the first radial position of the pistol grip of the handle aligns the fillable bladder with a targeted exterior portion of the heart (when the pistol grip of the handle is held by the one hand of the operator during the procedure to implant the cardiac implant). Optionally, the cardiac treatment system may include one or more additional features described in detail herein.
Further embodiments described herein include a method of treating heart valve insufficiency. The method may include introducing a cardiac device into a patient. The cardiac device can include an implant body comprising a mesh material and configured to surround at least a portion of the patient's heart. Also, the cardiac device may include a fillable bladder mounted to the implant body. The method may optionally include positioning one or more radiopaque markers of the fillable bladder at a targeted exterior region of the patient's heart that is adjacent to a targeted valve structure. Additionally, the method may optionally include one or more additional features described in detail herein.
In some embodiments, a method of treating heart valve insufficiency includes introducing a cardiac implant into a patient. The cardiac implant may include an implant body, which can optionally be formed into a generally tubular configuration. The implant body may include a leading end portion with an open leading end and a trailing end portion with an open trailing end. The cardiac implant may also include a fillable bladder attached to the implant body. The method may also include positioning the cardiac implant along an exterior of the heart so that the leading end portion is positioned in an atrial-ventricular groove of the heart, the trailing end portion of the implant extends proximal of the apex of the heart, and the fillable bladder positioned adjacent a targeted exterior surface of the heart that is adjacent to selected valve structure. The method may optionally include closing the open trailing end of the trailing end portion of the implant body so that the implant body encompasses the apex of the heart. Optionally, the method may include one or more additional features described in detail herein.
In particular embodiments, a method includes introducing a cardiac implant into a patient, wherein the cardiac implant may include an implant body and a fillable bladder. The implant body may include a jacket of mesh material and a hem located around a perimeter of an open leading end of the implant body. Optionally, the hem may be formed from a portion of the mesh material and an elastic band surrounded by the portion of the mesh material. The fillable bladder can be attached on an interior of the mesh jacket. The fillable bladder may include an inner layer and an adjacent outer layer that is adjacent the mesh jacket. The inner layer may have a compliance that is greater than a compliance of the outer layer. The method may also include positioning the cardiac implant within the pericardium and external to the epicardium of a heart. Such positioning may occur so that the hem of the implant is positioned in an atrial-ventricular groove of the heart and the fillable bladder is positioned adjacent a portion of external heart wall that is adjacent to selected valve structure. The method may further include filling the fillable chamber whereupon the inner layer expands inwardly to apply localized pressure against the portion of the external heart wall that is adjacent the selected valve structure. Optionally, the method may include one or more additional features described in detail herein.
In some embodiments, a method may include introducing a cardiac implant into a patient. The cardiac implant may include an implant body and a fillable bladder mounted to the implant body. The fillable bladder may include an inner bladder layer having a compliance that is greater than a compliance of the outer bladder layer. Also, the method may include positioning the cardiac implant within the pericardium and around the epicardium of a heart so that the inner bladder layer of the fillable bladder is positioned adjacent a portion of external heart wall that is adjacent selected valve structure. The method may include filling the fillable chamber such that the bladder expands more inwardly toward the heart than outwardly away from the heart and applies localized pressure on the external heart wall. Optionally, the method may include one or more additional features described in detail herein.
Further embodiments described herein include a method for an operator to implant a cardiac implant for treating heart valve insufficiency. The method may include providing a delivery system loaded with a cardiac implant. The cardiac implant may include an open leading end and configured for implantation around external portions of a heart. The delivery system may include an implant delivery mechanism comprising a plurality of distally extending elongate members each having a distal end portion attached to a portion of the cardiac implant at or near the open leading end. The delivery system may further include a proximal handle assembly comprising a pistol grip. Also, the delivery system may include a control mechanism configured in relation to the plurality of elongate members for manually extending the plurality of elongate members relative to the handle assembly. The method may include implanting the cardiac implant with the operator holding the pistol grip of the handle assembly in a first hand, and using a second hand to actuate the control mechanism to extend manually the plurality of elongate members to advance the open leading end of the cardiac implant over and past the apex of the heart to position the cardiac implant around external portions of the heart. Optionally, the method may include one or more additional features described in detail herein.
Various embodiments described herein include a method of treating heart valve insufficiency. The method may include providing a cardiac implant including an implant body, an inflatable bladder arranged on the implant body, and flexible tubing in fluid communication with an internal chamber of the inflatable bladder. The method may also include implanting the cardiac implant around external portions of the heart with the inflatable bladder positioned adjacent a portion of an external heart wall that is adjacent to a targeted heart valve structure. Further, the method may include inflating the inflatable bladder using the flexible tubing. Optionally, the method may include attaching at least one biodegradable ligation clip to a proximal portion of the flexible tubing to seal an internal lumen of the flexible tubing to maintain a selected inflation state of the fillable bladder. Also, the method may optionally include one or more additional features described in detail herein.
Particular embodiments described herein include a method of making a cardiac implant. The method may provide a cardiac implant for implantation around an exterior of a heart. The method may include providing a first plate structure having opening structure on a surface thereof. The opening structure may accommodating adhesive radiopaque material. The method may also include providing a second plate structure having two fillable bladder sheet components positioned thereon. Further, the method may include positioning, to provide a cardiac implant pre-assembly, a portion of a mesh jacket between the first plate structure and the two fillable bladder sheet components positioned on the second plate structure. The method may also include curing the implant pre-assembly to attach the radiopaque marker material, provided through the opening structure, on one side of the portion of the mesh jacket and the two fillable bladder sheet components on an opposite side of the portion of the mesh jacket. Optionally, the opening structure of the first plate structure may include at least one indentation in the first plate structure into which the adhesive radiopaque material is provided. In another option, the opening structure may include at least one hole through the first plate structure through which hole adhesive radiopaque material is provided. Optionally, the method may include one or more additional features described in detail herein.
These and other embodiments described herein may provide one or more of the following benefits. First, some embodiments include an implant structure having a combination of components that operate to contemporaneously apply forces for supporting or deformation different targeted regions of the heart. For example, the implant structure of particular embodiments of the system described can be configured to contemporaneously apply a localized pressure to a defined area of the posterior lateral surface of the heart while also applying a restraining force of to the ventricle walls of the heart and (optionally) a compressive supporting force to the atrial-ventricular groove of the heart.
Second, some embodiments of the system or method described herein can be used to treat various heart conditions, including but not limited to functional mitral valve regurgitation (“FMR”), tricuspid valve regurgitation, congestive heart failure, or a combination thereof. Upon implantation, implantation structure can apply forces for supporting or deformation regions of the heart in a manner that eliminates or reduces the symptoms of these conditions and that improves blood flow from the heart.
Third, some embodiments of the system or method described herein can include a delivery device configured to advantageously advanced the implant structure to the heart through a relatively small opening of a selected intercostal space proximate to the apex of the heart. Optionally, each delivery device can be configured as a disposable, single-use instrument that is pre-loaded with the implant structure and packaged in a sterilized kit. As such, the clinician can simply select a delivery device bearing the selected size of implant structure (pre-installed on a barrel of the delivery device by during manufacture or assembly) from a plurality of delivery devices in a hospital inventory. After the implant structure in implanted, the delivery device can be conveniently discarded along with other disposables from the operating room.
Fourth, in some embodiments, the implant structure can be arranged on the delivery device in a predetermined orientation relative to the handle of the delivery device. In such circumstances, the fillable bladder of the implant structure may be predisposed for advancement along a targeted side of the heart (e.g., a posterior side) when the handle of the delivery device is held in a selected position external to the opening in the chest, thereby assisting the clinician in aligning the fillable bladder with the targeted surface region of the heart.
Fifth, in particular embodiments, the implant structure can be equipped with radiopaque markers positioned at an advantageous combination of locations along the leading end, along the fillable bladder, or both. As such, during use of the implant structure, the relative positioning of the implant structure and the targeted landmarks of the heart can be readily identified both during and after an implantation procedure.
The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of such embodiments will be apparent from the description and drawings, and from the claims.
Referring to
Referring to
In some embodiments, the implant 100 can include a tubular mesh body 110. The tubular mesh body 110 may include one or more seams 111 that are formed as a result of the construction of the tubular mesh body 110. For example, the one or more seams 111 may be formed as a result of making the mesh body 110 into a tube, as a result of creating contours within the mesh body 110, or as a result of creating hemmed ends of the mesh body 110. However, seams are not a requirement in all embodiments of the implant described herein. That is, in some alternative embodiments, the implant can be made with a seamless construction.
Still referring to
An inflation tube 130 is in fluid communication with the fillable bladder 120. As described further herein, the inflation tube 130 provides a lumen through which an inflation fluid (e.g., saline or another biocompatible liquid) is transferred to thereby inflate or deflate the fillable bladder 120. In some embodiments, one or more ligation clips 140 are used to seal the inflation tube 130 after the fillable bladder 120 has been filled with an inflation fluid to a desired extent. As an alternative to the ligation clips 140, the inflation tube 130 can be doubled over to seal the inflation tube 130, and the configuration can be secured by tightly wrapping the doubled-over portion with a suture. In another alternative, a plug can be inserted into the end of the inflation tube 130. Other techniques and a combination of techniques can also be used to seal the proximal region of inflation tube 130. With the one or more ligation clips 140 installed on the inflation tube 130, the selected amount of inflation fluid can be maintained within the fillable bladder 120. With the fillable bladder 120 thusly inflated, the expansion of the bladder 120 causes a localized pressure to be applied to a selected exterior surface of the heart H (e.g., along an exterior of the epicardium), to thereby treat a heart condition.
The implant 100 can also include a plurality of radiopaque markers 115 and 125 in selected locations that provide a number of benefits to a surgeon during and after implantation. Such radiopaque markers 115 and 125 can facilitate radiographical visualization of the implant 100 during a minimally invasive implantation process. For example, in some instances the implant 100 is installed with the assistance of fluoroscopy. Other imaging modalities may also be used, such as echocardiography, Mill, and the like. Using imaging systems in conjunction with radiopaque markers 115 and 125, the implant 100 can be positioned onto the heart H, and oriented in relation to anatomical features of the heart H, as desired. In some implant procedures, contrast agent solutions are injected into the heart, or within the pericardial space, to enhance the radiographical visualization of anatomical features of the heart H on which an implant 100 is to be installed. The radiopaque markers 115 and 125 can comprise materials such as, but not limited to, tantalum, platinum, tungsten, palladium alloys, and the like.
In the embodiment shown, a first group of radiopaque markers 115 are positioned at a leading end 112 of the mesh body 110. The leading end 112 in this embodiment includes a circumferential hem region that defines the distal end opening 117 (refer to
Still referring to
Referring now to
In the depicted embodiment, the fillable bladder 120 is attached to an interior surface of the mesh body 110 such that, when the implant 100 is implanted, the fillable bladder 120 is positioned between the mesh body 110 and the heart H. In other words, a surface of the fillable bladder 120 is in direct contact with a surface of the heart H (e.g., an exterior epicardial surface in this embodiment). When an inflation fluid is supplied under pressure into the fillable bladder 120 (e.g., from a syringe device coupled to the inflation tube 130), the fillable bladder 120 expands from a collapsed condition to an operative condition to thereby exert a localized pressure to a targeted portion of the surface of the heart H. A target location for applying the localized pressure can be strategically selected to induce a desired effect to the patient's heart H. For example, as shown, a localized pressure can be exerted at a location on the heart H that causes a deflection to an annulus of a heart valve HV, such as a mitral valve or a tricuspid valve. In that manner, some types of valvular regurgitation can be treated. In a particular example, the fillable bladder 120 can be positioned to exert a localized pressure on the posterior lateral surface of the heart H to thereby deflect the “P2” portion of the posterior leaflet of the mitral valve to treat FMR. In another example, other areas on the exterior surface of the ventricles V can be targeted for the exertion of a localized pressure from the fillable bladder 120. In some such examples, the papillary muscles P are advantageously deflected. In certain instances, such deflecting of the papillary muscles P, and the chordae tendineae CT confluent therewith, can also treat valvular regurgitation.
While the examples of
In some embodiments, the mesh body 110 is sized to snugly fit on the heart H, but not so tight as to cause a significant increase in left ventricular pressure during diastole or obstructions to the coronary arteries or other vessels such as the coronary sinus. That is, in these embodiments, the mesh body 110 is designed to be highly compliant to the shape of the heart H, and adaptable to gently conform with the distension of the myocardium as the heart H performs pumping actions.
Referring to
In some embodiments, the material of the mesh body 110 is constructed from a knitted, biocompatible material. In particular embodiments, the knitted material is made using a construction known as “Atlas knit.” The Atlas knit is a knit of fibers having directional expansion properties. More specifically, the knit, although formed of generally inelastic fibers, permits a construction of a flexible fabric at least slightly expandable beyond a rest state. The fibers of the mesh fabric are woven into two sets of fiber strands. The strands are interwoven to form the fabric with a first set of strands generally parallel and spaced-apart and with a second set of strands generally parallel and spaced-apart. For purposes of illustration in
In some embodiments, the mesh body 110 includes a leading end portion 114, a transition portion 116, and a trailing end portion 118. Each of the three portions 114, 116, and 118 are tubular. That is, the mesh material used to construct the portions 114, 116, and 118 is arranged to define open interior spaces. In this embodiment, the mesh body 110 is configured to provide a cross-section shape (e.g., perpendicular to a central axis of the implant 100) that is circular in each of the three portions 114, 116, and 118, and the portions 114 and 118 may be generally cylindrical along a majority of their respective axial lengths. In other embodiments, the materials can be arranged to define other cross-sectional shapes. In other embodiments, other configurations of implant body shapes are envisioned, and such portions 114, 116, and 118 are not necessarily implemented in all embodiments described herein. In some embodiments, the construction of the mesh body 110 may include one or more seams 111 as a result of sewing the mesh material into the desired shape. In some embodiments, the construction of the mesh body 110 may be seamless.
Still referring to
In some embodiments, at least a portion of the leading end portion 114 has a diameter and construction for positioning around a heart in the atrial-ventricular groove AV of the heart H. For example, a hem 113 comprising an elastic band member may be configured for positioning around an atrial-ventricular groove AV (refer to
Portions of the leading end portion 114, other than the hem 113, are configured for circumferentially encompassing upper portions of the heart ventricles. In addition, some or all of the transition portion 116 may be configured for circumferentially encompassing other portions the heart ventricles. Most or all of the trailing end portion 118 may be configured to extend proximally from the apex of the heart when the leading end 112 is positioned in the atrial-ventricular groove. After installation of the implant 100 on a heart, some or all of the trailing end portion 118 may be trimmed away and removed from the implant 100. Thereafter the trimmed proximal end of the implant 110 may gathered or cinched and closed around the apex of the heart. Closing the proximal open end prevents the implant 100 from migrating toward the superior regions of the heart after implantation. In this manner, the implant 100 can be tailored to fit the patient-specific size and contours of the heart on which the implant 100 is installed.
Multiple sizes of implants 100 are envisioned that are suitable for treating multiple sizes of hearts. For example, the diameters of some or all of portions 114, 116, and 118 can be available in incremental sizes. In some embodiments, the axial lengths of some or all of portions 114, 116, and 118 are also configured in incremental sizes. As will be described further herein, an implant 100 of a particular size can be selected for a patient based on a pre-operative measurement of the patient's heart. For example, in some instances a measurement is taken of the patient's largest ventricular perimeter, and that measurement is used to select the size of implant 100 to be used for that patient. As will be described further herein, various sizes of implants 100, each of which is preloaded on an implant delivery device (refer to
Still referring to
As previously described, some embodiments of the implant 100 include multiple radiopaque markers 115 located around the hem 113 and multiple radiopaque markers 125 located around the periphery of the fillable bladder 120. As described previously, various types of radiopaque markers can be used. In some embodiments, the radiopaque markers 115 and 125 have an adhesive quality during manufacture of the implant 100 that can be used advantageously during the construction of the implant 100. For example, the second group of radiopaque markers 125 can be adhered to the mesh body 110 and, via the interstitial spaces of the mesh, adhered to the fillable bladder 120 to thereby affix the fillable bladder 120 to the implant 100. In one such embodiment, the radiopaque markers 125 (and 115) can be made from raw materials such as a silicone adhesive paste mixed with powdered tantalum. During manufacturing of the implant 100, the mixture can be injected into depressions residing in a metal plate, and that are configured in a generally rectangular pattern as defined by the radiopaque markers 125 shown in the implant 100. The metal plate can thereby act as a mold for forming the radiopaque markers 125. The mesh body 110 can be placed over the metal plate in an orientation that will position the fillable bladder 120 as desired in relation to the mesh body 110. The fillable bladder 120 can be placed on top of the mesh body 110 in an orientation so as to locate the radiopaque markers 125 around the periphery of the fillable bladder 120. A second metal plate can be positioned over the fillable bladder 120. The second metal plate may have a depression that corresponds to the fillable bladder 120. The stacked assembly can then be heated to cure the silicone adhesive paste. In the process, the radiopaque markers 125 become adhered to the mesh body 110 and to the fillable bladder 120. In this manner, the radiopaque markers 125 can be used to affix the fillable bladder 120 to the mesh body 110. Using a similar technique, the radiopaque markers 115 can be formed and adhered to the exterior layer of the mesh material of the hem 113, and adhered to the internal elastic band of the hem 113. Furthermore, the elastic band can thereby be “staked” in relation to mesh material of the hem 113 at the locations of the radiopaque markers 115. In other embodiments, the fillable bladder 120 and/or elastic band of the hem 113 can be affixed to the mesh body 110 using other bonding techniques, such as adhesives, mechanical clips, sutures, interweaving, ultrasonic welding, RF welding, and the like.
Still referring to
As previously described, the inflation tube 130 is in fluid communication the fillable bladder 120. The inflation tube 130 is of a flexible tubular construction and is configured to remain in the patient's body as part of the implant 100, and to remain in fluid communication with the fillable bladder 120. The free end of the inflation tube 130 can be positioned subcutaneously, and near to the underside of the epidermis. In some implementations, the free end of the inflation tube 130 is located in an intercostal space after implantation of the mesh body 110 around the heart. So locating the free end of the inflation tube 130 may allow future access to the inflation tube 130 via a simple cut-down procedure through the skin adjacent to the intercostal space between the ribs (e.g., the fifth intercostal space in some implementations). Future inflation or deflation of the fillable bladder 120 may thereby be performed with a minimally invasive access to an intercostal space under the side without extensive surgery to access the pericardium or epicardium.
In some embodiments, the flexible inflation tube 130 is made of silicone, but other biocompatible materials may also be used. In some embodiments, the outer diameter of the inflation tube 130 can range from about 0.065 inches to about 0.25 inches (about 1.60 mm to about 6.40 mm). In one example embodiment, the outer diameter of the inflation tube is about 0.125 inches (about 3.2 mm). In some embodiments, the inner diameter of the inflation tube 130 can range from about 0.031 inches to about 0.125 inches (about 0.78 mm to about 3.18 mm). In one example embodiment wherein the outer diameter of the inflation tube is about 0.125 inches (about 3.2 mm), the inner diameter of the inflation tube is about 0.0625 inches (about 1.58 mm). Such inflation tube dimensions are provided as examples, and it should be understood that other sizes are also envisioned within the scope of this disclosure. In addition, the cross-sectional sizing of the inflation tube may be selected to accommodate the specific inflation material (and in some cases radiopaque contrast agent) that will flow through the tube (discussed below).
The inflation tube 130 provides a flexible conduit through which inflation fluid can be conveyed to inflate or deflate the fillable bladder 120. After inflating or deflating the fillable bladder 120 with a selected volume of inflation fluid, the proximal end region of the inflation tube 130 is sealed to prevent withdrawal of the inflation fluid from the fillable bladder 120. Various types of inflation fluids can be used. For example, the inflation fluid can be a saline liquid solution, silicone gel, gaseous substances, and fluids containing a contrast agent that facilitate visualization of the inflation fluid via imaging systems.
In some embodiments, the fillable bladder 120 is configured of two different sheet components 122 and 124 so that the bladder 120, when inflated, expands more interiorly (that is, toward the heart wall when implanted) than exteriorly. As such, the bladder 120 is configured to provide a differential compliance in which one surface of a bladder 120 is significantly more compliant than the opposing (less compliant) surface of the bladder 120. In the context of fillable bladder 120, the interior sheet component 122 of the fillable bladder 120 is more compliant than the outer sheet component 124 of the fillable bladder 120. When the implant 100 is installed on a heart, the heart is located within the interior region of the mesh body 110 and in contact with the interior sheet component 122 of the fillable bladder 120. The greater compliance of the interior sheet component 122 of the fillable bladder 120 (in relation to the lesser compliance of the outer surface material) can accentuate the localized pressure applied onto the surface of the heart when the fillable bladder 120 is inflated.
Referring now to
The material of the interior sheet component 122 can be selected to have a higher compliance than the material selected for the outer sheet component 124. The interior sheet component 122 can be made of a silicone sheet material, or other biocompatible airtight sheet materials. In some embodiments, the thickness of the interior sheet component 122 is in the range of about 0.005 inches to about 0.050 inches (about 0.12 mm to about 1.30 mm). In one example embodiment, the interior sheet component 122 is a silicone sheet material that is about 0.015 inches (about 0.38 mm) in thickness. The outer sheet component 124 can also be made of a silicone sheet material, or other biocompatible airtight sheet materials. In some embodiments, the material of the outer sheet component 124 can be reinforced (e.g., with a polyester mesh that is impregnated into the sheet) to resist deformation, thereby reducing the compliance of the outer sheet component 124. In some embodiments, the thickness of the outer sheet component 124 is in the range of about 0.005 inches to about 0.070 inches (about 0.12 mm to about 1.78 mm). In one example embodiment wherein the interior sheet component 122 is a silicone sheet material that is about 0.015 inches (about 0.38 mm) in thickness, the outer sheet component 124 is a reinforced silicone sheet material that is about 0.020 inches (about 0.51 mm) in thickness.
Various sizes of inflatable bladders 120 can be constructed, and differently sized inflatable bladders 120 can be used with differently sized implants. In some embodiments, the length and width dimensions of the sheet components 122 and 124 (including the peripheral regions of the membranes that are sealed together) can be in a range from about 0.5 inches to about 4.0 inches (about 12.7 mm to about 101.6 mm). In one example embodiment, the length and width dimensions of the membranes 122 and 124 are in a range from about 1.075 inches to about 2.265 inches (about 27.30 mm to about 57.53 mm). In some embodiments, the fillable bladder 120 has a peripheral seal that is about 0.25 inches (about 6.35 mm) wide, and the sheet material within the peripheral seal is the inflatable portion.
In this embodiment, the peripheral bonding of the sheet components 122 and 124 can be accomplished using the bonding agent 126. The bonding agent 126 can cross-link with the materials of the sheet components 122 and 124 when the bonding agent 126 and sheet components 122 and 124 are heat-soaked as an assembly. In one example, the assembly is heat-soaked at about 350 F (about 177 C) for about 2 hours. Other heat-soaking time and temperature combinations can also be used, and lower temperatures will tend to require longer durations (and vice versa). Various types of bonding agents 126 can be used. In a preferred embodiment, the bonding agent 126 is a non-vulcanized silicone sheet that is about 0.010 inches (about 0.25 mm) thick. After the bonding of the inner and sheet components 122 and 124, and the inflation tube 130, the fillable bladder 120 can be leak tested to confirm that the fillable bladder 120 is hermetically sealed.
Upon implantation and proper positioning of the fillable bladder 120 with respect to targeted heart H structure(s), the fillable bladder 120 (and specifically the bladder's interior sheet component 122) is located and bears against an outer epicardial wall of the heart H, and the mesh material of the mesh body 110 that is located exteriorly of the bladder 120 faces outwardly and bears against the pericardium. When the bladder 120 is inflated, the interior sheet component 122 of the bladder 120 expands inwardly (e.g., expansion from a reference plane defined as extending through the sealed periphery region of the bladder 120) more so than the outer sheet component 124 of the bladder 120 expands outwardly from this reference plane. This characteristic is accentuated in larger bladder embodiments in comparison to smaller bladder embodiments. Therefore, design selections, including interior and outer sheet properties as well as bladder size and other parameters, can be made to attain a fillable bladder with the desired expansion characteristics.
The combination of the implant's mesh body 110 located exteriorly of the bladder 120 (which provides an circumferential restraint force to urge the bladder 120 toward the heart H) and the presence of the pericardium that surrounds the heart H (the pericardium providing a bearing surface against which the implant's mesh material and hence the outer sheet component 124 of the bladder 120 bears) collectively resist outward movement of the bladder 120. This resistance to outward movement of the bladder 120 from the heart H also contributes so that the interior sheet component 122 of the bladder provides localized pressure upon the targeted surface region of the heart. This localized pressure deforms not only the targeted surface region of the heart wall, but also valve structures located inside the chambers of the heart in the location of the localized pressure (refer to
As seen in
In one example embodiment, jacket 10 is made of a suitable knit material. An example of such a knit material may be “Atlas Knit” material described above. Alternatively, jacket 10 may be elastic. Optionally, the fibers may be made of Denier polyester. However, other suitable materials, including but not limited to, PTFE, ePTFE, polypropylene and stainless steel may also be used. Advantages of using a knit material include flexibility, fluid permeability and minimizing the amount of heart surface area in direct contact with the jacket (thereby minimizing the potential of scar tissue development).
Inflatable bladder 20 is disposed on an interior surface of jacket 10. Bladder 20 may or may not be attached to jacket 10.
As seen in
As discussed previously, bladder 20 may be inflated with fluids including air, inert gasses (such as fluorocarbons), silicone gel, saline and contrast agents. Supply lines 25 may optionally be inflated through a blunt needle port, a Luer port fitting, a subcutaneous port 26, etc. In other embodiments, a port-type device may not be used, and instead, the supply lines may be clamped in a closed position, as described previously. Supply lines 25 are made of a suitable bio-compatible material, including but not limited to silicone. This document includes a disclosure of various mechanisms for inflating and deflating bladders 20 post-implementation. For example, in one approach the device is first received onto the heart. After a period of time (e.g.: 30 days) fibrotic encapsulation of mesh jacket 10 will have occurred. At this time, the bladder(s) 20 can then be inflated (through supply line 25 using a needle to percutaneously access filling reservoir 26). Thus, subcutaneous ports 26 may be employed for percutaneous inflation and deflation for therapy optimization or abandonment. Alternatively, and because in some cases implanted subcutaneous port-type devices may have potential drawbacks, clamping of the fluid path tube may be done, with the fluid path staying in the intercostal space and may be accessed by a small “cut-down” procedure to access the tube.
In optional embodiments, jacket 10 has an elastic band 14 passing around its top end 12, as described previously. In addition, radiopaque markers 15 can also be provided around top end 12 of the implant 1.
The present jacket and bladder implant system 1 can be placed around the patient's heart in a variety of different approaches. In an example method of use, the present system further includes a delivery device for positioning the jacket onto the heart, as described later in this document. In one example of the method described later in this document, the assembly is implanted into the patient in a left intercostal mini-thoracotomy using contrast pericardiography and fluoroscopic visualization. After opening the parietal pericardium, the lower portion of the heart is free for applying the jacket over the apex.
In some embodiments, methods of providing localized pressure to a region of a patient's heart H to improve heart functioning may be performed by: (a) positioning an assembly around a patient's heart, wherein the assembly comprises a jacket 10 and at least one inflatable bladder 20, wherein jacket 10 is made of a flexible biocompatible material having an open top end 12 that is received around the heart and a bottom portion 14 that is received around the apex of the heart, and the inflatable bladder 20 is disposed on an interior surface of the jacket, and the inflatable bladder 20 has an inelastic outer surface positioned adjacent to the jacket and an elastic inner surface. In addition, bladder 20 may be inflated causing it to expand such that the bladder deforms substantially inwardly to exert localized pressure against a region of the heart.
In another method of use, a pericardial edge management system (PEMS) may be used in the surgical procedure for safe introduction of the implant 1. A PEMS includes multiple separate sheets that each have one “peel and stick” side, and may be made of Teflon. These sheets can be used to keep the opening into the pericardium open to facilitate insertion of the device without damage to the pericardium (i.e., the insertion tool getting hung up on the edges of the opening). In addition, the PEMS can be used to initially separate the heart from the mesh fabric. After all of the PEMS sheets are pulled out, the jacket fabric can then engage the heart.
Referring to
In this embodiment, the implant 100 is loaded onto the delivery device 200 at a distal end of the delivery device 200. A main body 210 of the delivery device 200 is located near a proximal end of the delivery device 200. A barrel assembly 220 extends from the main body 210 to the distal end of the delivery device 200. The implant 100 surrounds and is coupled to a distal end of the barrel assembly 220. A proximal end of the barrel assembly 220 is attached to the main body 210. A heart stabilizer assembly 230, which may be configured to releasably anchor to the apex of the hearth H during an implantation procedure, extends from a proximal end of the main body 210 to the distal end of the barrel assembly 220.
In some embodiments, the delivery device 200 and the implant 100 are pre-assembled and packaged together in sterile packaging. That is, the delivery device 200 can be provided to a clinician with the implant 100 pre-loaded onto the delivery device 200 and ready for sterile use. As described elsewhere herein, implants 100 of various sizes are used in order to properly fit multiple sizes of hearts. Therefore, a hospital that performs procedures to install the implants 100 may keep an inventory of various sized implants 100, each of which is pre-loaded on a particular delivery device 200 and packaged in sterile packaging. After the clinician determines the size of patient's heart, the clinician can select from the hospital's inventory the implant 100 that is sized to best fit the patient's heart. The clinician will receive a sterile delivery device 200 that is pre-loaded with that selected size of implant 100. After the implant 100 is deployed from the delivery device 200, the delivery device 200 may be discarded as a single-use instrument (for those embodiments in which the delivery device 200 is packaged as a single-use device).
Still referring to
The barrel assembly 220 of the delivery device 200 may optionally include a splined elongate barrel 222 for guiding the actuators 224 of the delivery device 200. In this embodiment, six actuators 224 are included around the periphery of the barrel 222. In other embodiments, fewer or more than six actuators can be included in a delivery device. The actuators 224 are each individually slidably coupled to a spline of the barrel 222. The actuators 224 are also each individually releasably coupled to an epicardial management strip 250. In this embodiment, there are a total of six epicardial management strips 250. The epicardial management strips 250 extend from the actuators 224, on the external surface of the barrel 222, under the implant 100, and terminate where the implant 100 is coupled to the delivery device 200. The epicardial management strips 250 provide low-friction surface area that facilitates the advancement of the implant 100 onto a heart. The epicardial management strips 250 are not shown in
Still referring to
In this embodiment, the vacuum connection fitting 232 is a barbed fitting. Other types of fittings can also be used, such as luer connections, compressing fittings, threaded fittings, quick-lock fittings, and the like. A source of negative pressure (vacuum) can be connected via flexible tubing (not shown) to the vacuum connection fitting 232. The negative pressure will be communicated from the vacuum connection fitting 232, through the vacuum tube 236, and to the vacuum cup 238.
The shaft rack 234 of the heart stabilizer assembly 230 is configured to be releasably engageable with the lock release button 214. Engagement between the shaft rack 234 and the lock release button 214 effectuates the locking of the heart stabilizer assembly 230 in a selected axial position in relation to the main body 210 and barrel assembly 220. Disengagement of the shaft rack 234 and the lock release button 214 (when the lock release button 214 is depressed) unlocks the heart stabilizer assembly 230 such that the heart stabilizer assembly 230 can move axially in relation to the main body 210 and barrel assembly 220.
In this embodiment, the shaft rack 234 includes a series of holes with which one or more protrusions on the shaft lock release button 214 engage. When the lock release button 214 is extending outward from the main body 214 (which is the default position of the button 214), the one or more protrusions on the lock release button 214 extend into one or more holes on the shaft rack 234 to lock the heart stabilizer assembly 230 in place. In contrast, when the lock release button 214 is depressed towards the main body 214 (e.g., by manually pushing the button 214), the one or more protrusions on the lock release button 214 become disengaged from the holes on the shaft rack 234. As a result of depressing and maintaining the lock release button 214 in a depressed position, the heart stabilizer assembly 230 becomes unlocked and free to move axially in relation to the other parts of the delivery device 200. That is the case because depressing and maintaining the lock release button 214 in a depressed position disengages the protrusions of the lock release button 214 from the holes of the shaft rack 234. When the lock release button 214 is no longer maintained in the depressed position, the outward bias of the lock release button 214 causes the button 214 to translate to an extended position to once again lock the heart stabilizer assembly 230 in relation to the other parts of the delivery device 200.
In one example, a comparison of
Various other design embodiments for locking and unlocking the heart stabilizers are also envisioned. Such embodiments can include the use of, but are not limited to, eccentric collars, cam mechanisms, interlocking tapers, over-center devices, set screws, and the like.
Still referring to
In this embodiment illustrated in
Referring now to
The epicardial management strips 250 can be made from a variety of different materials, including but not limited to, polytetrafluoroethylene (PTFE), expanded-PTFE (ePTFE), ultra-high-molecular-weight polyethylene (UHMWPE), fluorinated ethylene propylene (FEP), perfluoroalkoxy (PFA), and the like. In some embodiments, a lubricious coating or surface treatment can be applied to the material used to make the epicardial management strips 250. The materials selected to construct the epicardial management strips 250 have properties such as a low coefficient of friction, biocompatibility, and resistance to absorption of liquids. The thickness of the epicardial management strips 250 can be selected to provide the desired levels of lateral flexibility, column strength, and other mechanical properties. For example, in some embodiments the thickness of the epicardial management strips 250 are in the range of about 0.010 inches to about 0.100 inches (about 0.25 mm to about 2.54 mm).
In this embodiment, there are a total of six epicardial management strips 250. The epicardial management strips 250 extend from the actuators 224, over the external surface of the barrel 222, under the implant 100, and terminate where the implant 100 is coupled to the delivery device 200. In this embodiment, the epicardial management strips 250 include a proximal portion 252, a distal portion 254, and an intermediate portion 256 therebetween. The proximal portion 252 includes a first clearance hole 253 that is configured to engage with a barbed protrusion located on the actuators 224. The distal portion 254 is a widened area that slides on the heart's surface as an implant 100 is being installed. A second clearance hole 255 is located at the distal portion 254. The second clearance hole 255 is configured to allow a portion of the mesh material of the implant 100 to pass therethrough, whereafter the portion of mesh material is releasably coupled with the delivery device 200.
Referring now to
The arm assemblies 240 extend from the distal end of the barrel assembly 220 and terminate at free ends 244. A proximal end of each arm assembly 240 is coupled to an actuator 224. In this embodiment, the delivery device 200 includes six actuators 224 and six corresponding arm assemblies 240. Other embodiments may include more than six or fewer than six actuators and arm assemblies. In this embodiment, each actuator 224 is coupled to one and only one arm assembly 240, and each arm assembly 240 is coupled to one and only one actuator 224. However, in some embodiments, more than one arm assembly may be coupled to one actuator. As described further herein, the distal free ends 244 of the arm assemblies 240 are configured to releasably couple with the mesh material of an implant (refer, for example, to
Referring to
In this embodiment of the delivery device 200, the elongate arm assemblies 240 can be manually adjusted between a retracted position (depicted in
In the depicted embodiment, the arm assemblies 240 can be extended and retracted by moving the arm actuators 224. That is the case, because the proximal ends of the arm assemblies 240 are coupled to the actuators 224. In order to axially move an arm assembly 240, the corresponding actuator 224 can be slid along the splined elongate barrel 222. For example, because the actuators 224 are located near the proximal end of the splined elongate barrel 222 in
Referring to
In this embodiment of the delivery device 200, the actuators 224 and the arm assemblies 240 are each individually slidably coupled with a spline 223 of the barrel 222. Each arm assembly 240 can be at least partially disposed in a corresponding spline 223 of the splined elongate barrel 222. For example, arm assembly 240a is partially disposed in spline 223a. The open space defined by the splines 223 is larger than the outer profile of the portion of the arm assemblies 240 disposed therein. As such, the arm assemblies 240 are free to slide axially within the splines 223. The arm actuators 224 are also partially disposed in or engaged with a particular spline 223. For example, arm actuator 224a is engaged with spline 223a. The arm actuators 224 include shuttle portions that have shapes that are complementary to the shape of the splines 223. As a result, the arm actuators 224 are coupled to, and are slidable in relation to, the splines 223.
Referring to
The actuator lock ring 216 can be rotatably coupled to the main body 210. That is, in this embodiment the actuator lock ring 216 is coupled to, and is free to be manually rotated in relation to the main body 210. In addition, the actuator lock ring 216 can be manually rotated in relation to the barrel 222 and the arm actuators 224 slidably coupled thereto.
The actuator lock ring 216 includes a rotatable lock knob 218 that can be manually rotated to lock or unlock the actuators 224 to the main body 210. The actuator lock ring 216 also includes six slots 217 (shown in
In the cross-sectional view of
Referring now to
As described previously, arm actuators 224 are coupled to corresponding arm assemblies 240. For example, when an arm actuator 224 is axially translated in relation to the splined barrel 222, a corresponding arm assembly 240 is extended or retracted from the distal end 221 of the barrel 222. As each arm assembly 240 is extended or retracted, the hollow outer jacket 241, core member 242, and arm cap 243 of the arm assembly 240 can be extended or retracted in equal distances, and in unison.
The arm actuators 224 are coupled to arm assemblies 240 in a second manner that allows each actuator 224 to move the core members 242 of the corresponding arm assembly 240 relative to the hollow outer jacket 241 and arm cap 243. In particular, the arm actuators 224 are coupled to the core members 242 such that pivoting an actuator lever 226 of an arm actuator 224 can advance or retract a core member 242 of an arm assembly 240 in relation to the outer jacket 241 and arm end 243 of the arm assembly 240. The pivotable actuator lever 226 of an actuator 224 controls the core member 242 of the arm assembly 240 to which the actuator 224 is coupled.
The pivotable actuator lever 226 is shown pivoted away from the barrel 222 in
This second manner by which arm actuators 224 are coupled to arm assemblies 240 can be operated independently of axially translating an arm actuator 224 in relation to the splined barrel 222 to extend or retract a corresponding arm assembly 240. So, for example, at any axial position of an arm actuator 224, the actuator lever 226 can be pivoted to advance or retract the core member 242. Further, the two movements (axial translation of an arm actuator 224 and pivoting of the actuator lever 226) can be performed contemporaneously.
The advancing and retracting of the core members 242 within the windows of the arm ends 243 can be advantageously used for releasably coupling an implant to the delivery device 200. In some embodiments, a portion of the mesh body 110 of the implant 100 can be crimped and contained within a window of an arm end 243 (refer, for example, to
Referring now to
Referring to
At step 304 in some implementations of the method 300, a location for an incision to access the patient's heart is selected, and then an incision through the patient's skin is made. In some embodiments, the selected location of the incision will allow access to the apex of the heart in alignment with the long axis of the heart. Such an incision can allow an implant delivery device to be inserted into the patient's chest cavity substantially coaxially with the heart (e.g., as in step 326). Therefore, the location for the incision can be made at least partly based on the location of the apex of the patient's heart as ascertained in step 302. In some implementations, an intercostal incision location is selected. For example, in particular implementations the fifth intercostal space may be selected. However, the selected incision location can be patient-specific. In some implementations, the incision comprises a mini-thoracotomy heart access procedure. In some embodiments of method 300, a minimum size of incision is recommended. For example, for the delivery device 200 described above, a minimum incision of 7 cm is recommended, although that is optional in some implementations.
At step 306 in some implementations of the method 300, surgical retraction is performed to create and maintain a surgical passageway through the patient's incised skin. In some implementations, a low-profile retractor is used. In some embodiments of method 300, a separation distance of the retractor blades is recommended. For example, when the delivery device 200 described above will be used, the retractor blades should be separated by at least about 4 cm.
At step 308 in some implementations of the method 300, the pericardium is incised and retracted to provide access to the heart's apex. In some embodiments, the selected location of the incision will allow access to the apex of the heart in alignment with the long axis of the heart. In some embodiments of method 300, a minimum size of incision is recommended. For example, for the delivery device 200 described above, a minimum incision of 7 cm is recommended, although that is optional. The edges of the pericardium can be retracted by suturing the edges to the surrounding tissues.
At step 310 in some implementations of the method 300, an inspection is made for pericardial adhesions. Pericardial adhesions are an attachment of the pericardium to the heart muscle. In some implementations, contrast agent solution may be injected into the pericardium to enhance visualization of pericardial adhesions. If pericardial adhesions that may impede complete circumferential access to the heart are identified, the clinician may abandon the method 300 at this point.
At step 312 in some implementations of the method 300, multiple pericardial edge management strips (PEMS) are installed. The PEMS can be used to cover exposed edges of the pericardium, and to create a clear tunnel for access (e.g., by delivery tool 200) to the apex of the heart. In some implementations, four to six PEMS are installed. In other implementations, fewer than four or more than six PEMS may be installed. The PEMS are sterile devices.
One example embodiment of PEMS is illustrated in
One non-limiting example of step 312 (using the PEMS 400) is illustrated in
Referring again to
In some implementations of the method 300, the optional step 316 includes intra-operatively measuring the ventricular perimeter of the patient's heart. In some instances, the measurement may have already been performed pre-operatively using imaging modalities such as a CAT scan, MRI, ultrasound, and the like. In such instances, step 316 may be optional to perform.
An example intra-operative sizing device 500 for performing step 316 is depicted in
In some embodiments, the main body 510 includes a casing 511, sizing positioners 512, a sizing indicator 513, and a sizing scale 514. The sizing positioners 512, which are linked to the sizing indicator 513, are slidable in relation to the casing 511. The sizing scale 514 is affixed to the casing. As the sizing positioners 512 are axially translated, the sizing indicator 513 moves in unison. The clinician can ascertain the measurement by viewing the sizing indicator 513 in relation to the sizing scale 514.
The sizing device 500 also includes a vacuum assembly 520. In some embodiments, the vacuum assembly 520 can include a vacuum fitting 521, a knob 522, a vacuum shaft 523, and a vacuum stabilizer cup 524. The aforementioned components of the vacuum assembly 520 are affixed to each other and axially translate in relation to the main body 510 as a unit. The vacuum fitting 52 is in fluid communication with the vacuum shaft 523, which is in fluid communication with the vacuum stabilizer cup 524. Hence, when a source of negative pressure is attached to the vacuum fitting, negative pressure is communicated to the vacuum shaft 523 and vacuum stabilizer cup 524.
In some embodiments, the sizing device 500 also includes multiple sizing arms 530. In the depicted embodiment, three arms 530 are included that are disposed at about 120 degrees apart from each other. In other embodiments, fewer or more arms are included. One end of the arms are affixed to the main body 510, while the other ends of the arms 530 are free ends having end caps 532. The arms 530 are laterally elastically flexible. That is, the arms 530 can radially deflect away from the vacuum shaft 523 while having one end affixed to the main body 510. As such, in some embodiments the arms 530 are made from a polymeric material such as Acrylonitrile Butadiene Styrene (ABS), Polyvinyl Chloride (PVC), Cellulose Acetate Butyrate (CAB), Polyethylene (PE), High Density Polyethylene (HDPE), Low Density Polyethylene (LDPE or LLDPE), Polypropylene (PP), Polymethylpentene (PMP), Polycarbonate (PC), Polyphenelyne Ether (PPE), Polyamide (PA or Nylon), and the like. The end caps 532 include clearance holes through which a sizing cord 540 freely passes.
The sizing device 500 also includes sizing cords 540. In the embodiment depicted, three sizing cords 540 are included. In other embodiments, fewer or more cords are included. The cords can be comprised of a biocompatible material such as, but not limited to, PTFE, ePTFE, polypropylene, polyglycolide, nylon, and other like materials. Each cord 540 have two ends. A first end of the cords 540 is attached to the sizing positioners 512, and a second end of the cords are individually attached to an end cap 532. Therebetween, the cords 540 individually pass through a clearance hole in an end cap 532.
In one embodiment, the process for using the sizing device 500 is as follows. A source of negative pressure is connected to the vacuum fitting 521. The vacuum assembly 520 is fully extended in relation to the main body 510. The vacuum stabilizer cup 524 is inserted through the chest incision and placed in contact with the apex of the heart. The main body 510, and sizing arms 530 affixed thereto, are carefully advanced into the pericardial cavity so that the arms 530 and the cords 540 surround the heart. An imaging system, such as a fluoroscope, can be used to provide visualization of the advancement. As the arms and cords 540 are advanced, the sizing positioners 512 may move distally in relation to the main body 510 as the cords 540 require additional length to surround the heart. The advancement is stopped when the sizer cords 540 are around the largest perimeter of the heart. The sizer positioners 512 are then carefully pulled back (manually) to remove any slack in the cords 540. Using fluoroscopy, the clinician confirms that the cords 540 are not over-tightened (e.g., that the heart is not indented by the cords 540). The clinician then observes the relative position of the sizing indicator 513 to the sizing scale 514. The clinician can thereby ascertain the size of the largest perimeter of the heart, and thereafter remove the sizing device 500.
Referring again to
At step 320 in some implementations of the method 300, a source of negative pressure is connected to the delivery device. In the context of the example delivery device 200, the negative pressure is attached to vacuum connection fitting 232. The negative pressure will be communicated to the vacuum cup 238 of the heart stabilizer 230.
At step 322 in some implementations of the method 300, the vacuum stabilizer is fully extended. In the context of the example delivery device 200, the heart stabilizer 230 is fully extended in relation to the main body 210.
At step 324 in some implementations of the method 300, the vacuum stabilizer is inserted through the incision and into pericardial tunnel. An example of this step is illustrated in
Referring now to
At step 328 in some implementations of the method 300, the vacuum stabilizer is applied to the apex of the patient's heart. The negative pressure at the delivery device is active at this step. Therefore, the vacuum stabilizer becomes attached to the apex using vacuum. The apex of the heart is thereby stabilized in relation to the delivery device.
At step 330, the arm actuators can be unlocked. In the context of the example delivery device 200, the clinician rotates the actuator lock ring 216, as previously described. Thereafter, all of the arm actuators 224 are not locked to the main body 210, and the arm actuators 224 can be slid in relation to the main body 210 and splined barrel 222 of the delivery device 200.
At optional step 332 in some implementations of the method 300, the heart can be temporarily elongated. The clinician can perform this step by exerting a slight directed pull on the delivery device in a proximal direction. Doing so may elongate the shape of the heart at the heart's apex and ease the initial deployment of the delivery tool's arms over the heart.
At step 334, the arms of the delivery device are incrementally extended while using imaging to view the position of the arms relative to the heart.
At step 336, the arms are further advanced to position the leading hem of the implant in the atrial-ventricular groove of the heart. This positioning of the implant in the atrial-ventricular groove is depicted in
At step 338, the delivery device is decoupled from the implant. In the context of the example delivery device 200, pivoting an actuator lever 226 of an arm actuator 224 can retract a core member 242 of an arm assembly 240 in relation to the outer jacket 241 and arm end 243 of the arm assembly 240 to decouple the arm assembly 240 from the implant 100. This process can be repeated for every arm assembly 240 to fully decouple the implant 100 from the delivery device 200.
At step 340 the arms of the delivery device can be retracted. For instance, using the delivery device 200 as an example, the arm actuators 224 can be slid proximally to withdraw each arm assembly while leaving the implant 100 on the heart H. The epicardial management strips 250 are also retracted along with the arms 240.
At step 342, the delivery device is withdrawn from the patient. The negative pressure source is discontinued, and then the entire delivery device is withdrawn. One non-limiting example of this step is illustrated in
Referring again to
Referring again to
Referring now to
At step 350, the pericardial edge management strips are removed. The removal can be performed by reversing the steps of the implementation procedure.
At step 352, excess mesh material of the implant is trimmed. This step 352, like all other steps in some implementations of the method 300, may be performed while the heart is beating. In such circumstances, the clinician can carefully gather the trailing end material of the implant in the area of the chest opening. Using a scissors or other cutting device, the clinician can trim the excess material. Care is taken to ensure a sufficient amount remains with the implant to close the implant around the apex of the heart. One non-limiting example of this step is illustrated in
Referring again to
Referring again to
At step 358, the end of the inflation tube is aligned in an intercostal space and the chest incision is closed. Aligning the end of the inflation tube in the intercostal space may allow future access to the inflation tube via a simple cut-down procedure through the skin adjacent to the intercostal space between the ribs (e.g., the fifth intercostal space in some implementations). Future inflation or deflation of the fillable bladder may thereby be performed with a minimally invasive access to an intercostal space under the side without extensive surgery to access the pericardium or epicardium.
A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the scope of the invention. Accordingly, other embodiments are within the scope of the following claims.
This application is a continuation of U.S. patent application Ser. No. 15/162,029 filed on May 23, 2016, which is a continuation of U.S. patent application Ser. No. 14/053,590 filed Oct. 14, 2013, which claims priority to U.S. Provisional Patent Application No. 61/713,351 filed on Oct. 12, 2012 by Hjelle et al., the contents of which are fully incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1682119 | Field | Aug 1928 | A |
| 1965542 | Colvin, Jr. | Nov 1933 | A |
| 1982207 | Furniss | Nov 1934 | A |
| 2138603 | Johnson | Nov 1938 | A |
| 2278926 | Hartwell | Apr 1942 | A |
| 2376442 | Mehler | May 1945 | A |
| 2992550 | Frith | Jul 1961 | A |
| 3384530 | Mercer et al. | May 1968 | A |
| 3452742 | Muller | Jul 1969 | A |
| 3551543 | Mercer et al. | Dec 1970 | A |
| 3587567 | Schiff | Jun 1971 | A |
| 3643301 | Weigl | Feb 1972 | A |
| 3732662 | Paxton | May 1973 | A |
| 3768643 | Bruno | Oct 1973 | A |
| 3811411 | Moeller | May 1974 | A |
| 3983863 | Janke et al. | Oct 1976 | A |
| 4035849 | Angell | Jul 1977 | A |
| 4048990 | Goetz | Sep 1977 | A |
| 4196534 | Shibamoto | Apr 1980 | A |
| 4403604 | Wilkinson et al. | Sep 1983 | A |
| 4428375 | Ellman | Jan 1984 | A |
| D273514 | Heilman et al. | Apr 1984 | S |
| 4466331 | Matheson | Aug 1984 | A |
| 4536893 | Parravicini | Aug 1985 | A |
| 4567900 | Moore | Feb 1986 | A |
| 4598039 | Fischer et al. | Jul 1986 | A |
| 4630597 | Kantrowitz et al. | Dec 1986 | A |
| 4637377 | Loop | Jan 1987 | A |
| 4690134 | Snyders | Sep 1987 | A |
| 4790850 | Dunn et al. | Dec 1988 | A |
| 4821723 | Baker, Jr. et al. | Apr 1989 | A |
| 4827932 | Ideker et al. | May 1989 | A |
| 4834707 | Evans | May 1989 | A |
| 4840626 | Linsky et al. | Jun 1989 | A |
| 4878890 | Bilweis | Nov 1989 | A |
| 4932972 | Dunn et al. | Jun 1990 | A |
| 4936857 | Kulik | Jun 1990 | A |
| 4957477 | Lundback | Sep 1990 | A |
| 4973300 | Wright | Nov 1990 | A |
| 4976730 | Kwan-Gett | Dec 1990 | A |
| 4984584 | Hansen et al. | Jan 1991 | A |
| 4995857 | Arnold | Feb 1991 | A |
| 5042463 | Lekholm | Aug 1991 | A |
| 5057117 | Atweh | Oct 1991 | A |
| 5074129 | Matthew | Dec 1991 | A |
| 5087243 | Avitall | Feb 1992 | A |
| 5131905 | Grooters | Jul 1992 | A |
| 5143082 | Kindberg et al. | Sep 1992 | A |
| 5150706 | Cox et al. | Sep 1992 | A |
| 5186711 | Epstein | Feb 1993 | A |
| 5188813 | Fairey et al. | Feb 1993 | A |
| 5192314 | Daskalakis | Mar 1993 | A |
| 5207725 | Pinkerton | May 1993 | A |
| 5224363 | Sutton | Jul 1993 | A |
| 5256132 | Snyders | Oct 1993 | A |
| 5279539 | Bohan et al. | Jan 1994 | A |
| 5290217 | Campos | Mar 1994 | A |
| 5336253 | Gordon et al. | Aug 1994 | A |
| 5339657 | McMurray | Aug 1994 | A |
| 5341815 | Cofone et al. | Aug 1994 | A |
| 5356432 | Rutkow et al. | Oct 1994 | A |
| 5366460 | Eberbach | Nov 1994 | A |
| 5383840 | Heilman et al. | Jan 1995 | A |
| 5385156 | Oliva | Jan 1995 | A |
| 5405360 | Tovey | Apr 1995 | A |
| 5409703 | McAnalley et al. | Apr 1995 | A |
| 5429584 | Chiu | Jul 1995 | A |
| 5507779 | Altman | Apr 1996 | A |
| 5524633 | Heaven et al. | Jun 1996 | A |
| 5533958 | Wilk | Jul 1996 | A |
| 5558617 | Heilman et al. | Sep 1996 | A |
| 5571088 | Lennox et al. | Nov 1996 | A |
| 5593441 | Lichtenstein et al. | Jan 1997 | A |
| 5603337 | Jarvik | Feb 1997 | A |
| 5611515 | Benderev et al. | Mar 1997 | A |
| 5647380 | Campbell et al. | Jul 1997 | A |
| 5695525 | Mulhauser et al. | Dec 1997 | A |
| 5702343 | Alferness | Dec 1997 | A |
| 5713954 | Rosenberg et al. | Feb 1998 | A |
| 5735290 | Sterman et al. | Apr 1998 | A |
| 5766216 | Gangal et al. | Jun 1998 | A |
| 5782746 | Wright | Jul 1998 | A |
| D399000 | Rothman et al. | Sep 1998 | S |
| 5800334 | Wilk | Sep 1998 | A |
| 5800528 | Lederman et al. | Sep 1998 | A |
| 5839842 | Wanat et al. | Nov 1998 | A |
| 5848962 | Feindt | Dec 1998 | A |
| 5853422 | Huebsch et al. | Dec 1998 | A |
| 5928250 | Koike et al. | Jul 1999 | A |
| 5931810 | Grabek | Aug 1999 | A |
| 5961440 | Schweich, Jr. et al. | Oct 1999 | A |
| 5972013 | Schmidt | Oct 1999 | A |
| 5976551 | Mottez et al. | Nov 1999 | A |
| 5990378 | Ellis | Nov 1999 | A |
| 6042536 | Tihon et al. | Mar 2000 | A |
| 6045497 | Schweich, Jr. et al. | Apr 2000 | A |
| 6050936 | Schweich, Jr. et al. | Apr 2000 | A |
| 6059715 | Schweich, Jr. et al. | May 2000 | A |
| 6076013 | Brennan et al. | Jun 2000 | A |
| 6077214 | Mortier et al. | Jun 2000 | A |
| 6077218 | Alferness | Jun 2000 | A |
| 6085754 | Alferness et al. | Jul 2000 | A |
| 6089051 | Gorywoda et al. | Jul 2000 | A |
| 6095968 | Snyders | Aug 2000 | A |
| 6123662 | Alferness | Sep 2000 | A |
| 6126590 | Alferness | Oct 2000 | A |
| 6155968 | Wilk | Dec 2000 | A |
| 6155972 | Nauertz et al. | Dec 2000 | A |
| 6162168 | Schweich, Jr. et al. | Dec 2000 | A |
| 6165119 | Schweich, Jr. et al. | Dec 2000 | A |
| 6165120 | Schweich, Jr. et al. | Dec 2000 | A |
| 6165121 | Alferness | Dec 2000 | A |
| 6165122 | Alferness | Dec 2000 | A |
| 6169922 | Alferness et al. | Jan 2001 | B1 |
| 6174279 | Girard | Jan 2001 | B1 |
| 6179791 | Krueger | Jan 2001 | B1 |
| 6183411 | Mortier et al. | Feb 2001 | B1 |
| 6190408 | Melvin | Feb 2001 | B1 |
| 6193646 | Kulisz et al. | Feb 2001 | B1 |
| 6193648 | Krueger | Feb 2001 | B1 |
| 6205747 | Paniagua Olaechea | Mar 2001 | B1 |
| 6206004 | Schmidt et al. | Mar 2001 | B1 |
| 6206820 | Kazi | Mar 2001 | B1 |
| 6221103 | Melvin | Apr 2001 | B1 |
| 6224540 | Lederman et al. | May 2001 | B1 |
| 6230714 | Alferness et al. | May 2001 | B1 |
| 6241654 | Alferness | Jun 2001 | B1 |
| 6260552 | Mortier et al. | Jul 2001 | B1 |
| 6261222 | Schweich, Jr. et al. | Jul 2001 | B1 |
| 6264602 | Mortier et al. | Jul 2001 | B1 |
| 6293906 | Vanden Hoek et al. | Sep 2001 | B1 |
| 6332863 | Schweich, Jr. et al. | Dec 2001 | B1 |
| 6332864 | Schweich, Jr. et al. | Dec 2001 | B1 |
| 6332893 | Mortier et al. | Dec 2001 | B1 |
| 6360749 | Jayaraman | Mar 2002 | B1 |
| 6370429 | Alferness et al. | Apr 2002 | B1 |
| 6375608 | Alferness | Apr 2002 | B1 |
| 6402679 | Mortier | Jun 2002 | B1 |
| 6402680 | Mortier | Jun 2002 | B2 |
| 6406420 | McCarthy et al. | Jun 2002 | B1 |
| 6409760 | Melvin | Jun 2002 | B1 |
| 6416459 | Haindl | Jul 2002 | B1 |
| 6416554 | Alferness et al. | Jul 2002 | B1 |
| 6425856 | Shapland et al. | Jul 2002 | B1 |
| 6432039 | Wardle | Aug 2002 | B1 |
| 6482146 | Alferness et al. | Nov 2002 | B1 |
| 6488618 | Paolitto et al. | Dec 2002 | B1 |
| 6494825 | Talpade | Dec 2002 | B1 |
| 6508756 | Kung et al. | Jan 2003 | B1 |
| 6514194 | Schweich, Jr. et al. | Feb 2003 | B2 |
| 6517570 | Lau et al. | Feb 2003 | B1 |
| 6520904 | Melvin | Feb 2003 | B1 |
| 6537198 | Vidlund et al. | Mar 2003 | B1 |
| 6537203 | Alferness et al. | Mar 2003 | B1 |
| 6541678 | Klein | Apr 2003 | B2 |
| 6544168 | Alferness | Apr 2003 | B2 |
| 6547716 | Milbocker | Apr 2003 | B1 |
| 6558319 | Aboul-Hosn et al. | May 2003 | B1 |
| 6564094 | Alferness et al. | May 2003 | B2 |
| 6567699 | Alferness et al. | May 2003 | B2 |
| 6569082 | Chin | May 2003 | B1 |
| 6572533 | Shapland et al. | Jun 2003 | B1 |
| 6575921 | Vanden Hoek et al. | Jun 2003 | B2 |
| 6579226 | Vanden Hoek et al. | Jun 2003 | B2 |
| 6582355 | Alferness et al. | Jun 2003 | B2 |
| 6587734 | Okuzumi et al. | Jul 2003 | B2 |
| 6589160 | Schweich, Jr. et al. | Jul 2003 | B2 |
| 6592514 | Kolata et al. | Jul 2003 | B2 |
| 6595912 | Lau et al. | Jul 2003 | B2 |
| 6602184 | Lau et al. | Aug 2003 | B2 |
| 6612978 | Lau et al. | Sep 2003 | B2 |
| 6612979 | Lau et al. | Sep 2003 | B2 |
| 6616596 | Milbocker | Sep 2003 | B1 |
| 6616684 | Vidlund et al. | Sep 2003 | B1 |
| 6620095 | Taheri | Sep 2003 | B2 |
| 6622730 | Ekvall et al. | Sep 2003 | B2 |
| 6629921 | Schweich, Jr. et al. | Oct 2003 | B1 |
| 6645139 | Haindl | Nov 2003 | B2 |
| 6663558 | Lau et al. | Dec 2003 | B2 |
| 6673009 | Vanden Hoek et al. | Jan 2004 | B1 |
| 6682474 | Lau et al. | Jan 2004 | B2 |
| 6682475 | Cox et al. | Jan 2004 | B2 |
| 6682476 | Alferness et al. | Jan 2004 | B2 |
| 6685627 | Jayaraman | Feb 2004 | B2 |
| 6685628 | Vu | Feb 2004 | B2 |
| 6689048 | Vanden Hoek et al. | Feb 2004 | B2 |
| 6695768 | Levine et al. | Feb 2004 | B1 |
| 6695769 | French et al. | Feb 2004 | B2 |
| 6701929 | Hussein | Feb 2004 | B2 |
| 6702732 | Lau et al. | Mar 2004 | B1 |
| 6709382 | Horner | Mar 2004 | B1 |
| 6716158 | Raman et al. | Apr 2004 | B2 |
| 6723038 | Schroeder et al. | Apr 2004 | B1 |
| 6723041 | Lau et al. | Apr 2004 | B2 |
| 6726696 | Houser et al. | Apr 2004 | B1 |
| 6726920 | Theeuwes et al. | Apr 2004 | B1 |
| 6727316 | Bremser | Apr 2004 | B1 |
| 6730016 | Cox et al. | May 2004 | B1 |
| 6746471 | Mortier et al. | Jun 2004 | B2 |
| 6755777 | Schweich, Jr. et al. | Jun 2004 | B2 |
| 6755779 | Vanden Hoek et al. | Jun 2004 | B2 |
| 6755861 | Nakao | Jun 2004 | B2 |
| 6764510 | Vidlund et al. | Jul 2004 | B2 |
| 6776754 | Wilk | Aug 2004 | B1 |
| 6793618 | Schweich, Jr. et al. | Sep 2004 | B2 |
| 6808488 | Mortier et al. | Oct 2004 | B2 |
| 6852075 | Taylor | Feb 2005 | B1 |
| 6852076 | Nikolic et al. | Feb 2005 | B2 |
| 6858001 | Aboul-Hosn | Feb 2005 | B1 |
| 6876887 | Okuzumi et al. | Apr 2005 | B2 |
| 6881185 | Vanden Hoek et al. | Apr 2005 | B2 |
| 6893392 | Alferness | May 2005 | B2 |
| 6896652 | Alferness et al. | May 2005 | B2 |
| 6902522 | Walsh et al. | Jun 2005 | B1 |
| 6902524 | Alferness et al. | Jun 2005 | B2 |
| 6908426 | Shapland et al. | Jun 2005 | B2 |
| 6918870 | Hunyor et al. | Jul 2005 | B1 |
| 6951534 | Girard et al. | Oct 2005 | B2 |
| 6997865 | Alferness et al. | Feb 2006 | B2 |
| 7022063 | Lau et al. | Apr 2006 | B2 |
| 7022064 | Alferness et al. | Apr 2006 | B2 |
| 7025719 | Alferness et al. | Apr 2006 | B2 |
| 7060023 | French et al. | Jun 2006 | B2 |
| 7077862 | Vidlund et al. | Jul 2006 | B2 |
| 7081086 | Lau et al. | Jul 2006 | B2 |
| 7112219 | Vidlund | Sep 2006 | B2 |
| 7155295 | Lau et al. | Dec 2006 | B2 |
| 7163507 | Alferness et al. | Jan 2007 | B2 |
| 7181272 | Struble et al. | Feb 2007 | B2 |
| 7189203 | Lau et al. | Mar 2007 | B2 |
| 7214180 | Chin | May 2007 | B2 |
| 7235042 | Vanden Hoek et al. | Jun 2007 | B2 |
| 7252632 | Shapland et al. | Aug 2007 | B2 |
| 7276022 | Lau et al. | Oct 2007 | B2 |
| 7291105 | Lau et al. | Nov 2007 | B2 |
| 7297104 | Vanden Hoek et al. | Nov 2007 | B2 |
| 7351200 | Alferness | Apr 2008 | B2 |
| 7354396 | French et al. | Apr 2008 | B2 |
| 7361139 | Lau et al. | Apr 2008 | B2 |
| 7366659 | Etter | Apr 2008 | B2 |
| 7390293 | Jayaraman | Jun 2008 | B2 |
| 7398781 | Chin | Jul 2008 | B1 |
| 7404793 | Lau | Jul 2008 | B2 |
| 7404973 | Lau et al. | Jul 2008 | B2 |
| 7410461 | Lau et al. | Aug 2008 | B2 |
| 7468029 | Robertson | Dec 2008 | B1 |
| 7621866 | Dietz et al. | Nov 2009 | B2 |
| 7651462 | Hjelle et al. | Jan 2010 | B2 |
| 7736299 | Klenk et al. | Jun 2010 | B2 |
| 7955247 | Levine et al. | Jun 2011 | B2 |
| 8092363 | Leinsing et al. | Jan 2012 | B2 |
| 8100821 | Hjelle et al. | Jan 2012 | B2 |
| 8109868 | Girard et al. | Feb 2012 | B2 |
| 8202212 | Hjelle et al. | Jun 2012 | B2 |
| 8277372 | Alferness et al. | Oct 2012 | B2 |
| 8617051 | Hjelle et al. | Dec 2013 | B2 |
| 20010016675 | Mortier et al. | Aug 2001 | A1 |
| 20010025171 | Mortier et al. | Sep 2001 | A1 |
| 20020019580 | Lau et al. | Feb 2002 | A1 |
| 20020029080 | Mortier et al. | Mar 2002 | A1 |
| 20020045798 | Lau et al. | Apr 2002 | A1 |
| 20020058855 | Schweich, Jr. et al. | May 2002 | A1 |
| 20020068849 | Schweich, Jr. et al. | Jun 2002 | A1 |
| 20020068850 | Vanden Hoek et al. | Jun 2002 | A1 |
| 20020077524 | Schweich, Jr. et al. | Jun 2002 | A1 |
| 20020091296 | Alferness | Jul 2002 | A1 |
| 20020133055 | Handl | Sep 2002 | A1 |
| 20020147406 | Von Segesser | Oct 2002 | A1 |
| 20020151766 | Shapland | Oct 2002 | A1 |
| 20020169358 | Mortier et al. | Nov 2002 | A1 |
| 20020169359 | McCarthy et al. | Nov 2002 | A1 |
| 20020169360 | Taylor et al. | Nov 2002 | A1 |
| 20020173694 | Mortier et al. | Nov 2002 | A1 |
| 20030032979 | Mortier et al. | Feb 2003 | A1 |
| 20030050529 | Vidlund et al. | Mar 2003 | A1 |
| 20030060895 | French et al. | Mar 2003 | A1 |
| 20030065248 | Lau et al. | Apr 2003 | A1 |
| 20030088149 | Raman et al. | May 2003 | A1 |
| 20030130731 | Vidlund et al. | Jul 2003 | A1 |
| 20030166992 | Schweich, Jr. et al. | Sep 2003 | A1 |
| 20030171641 | Schweich, Jr. et al. | Sep 2003 | A1 |
| 20030181928 | Vidlund et al. | Sep 2003 | A1 |
| 20030229260 | Girard et al. | Dec 2003 | A1 |
| 20030229265 | Girard et al. | Dec 2003 | A1 |
| 20030233023 | Khaghani et al. | Dec 2003 | A1 |
| 20040002626 | Feld et al. | Jan 2004 | A1 |
| 20040010180 | Scorvo | Jan 2004 | A1 |
| 20040034272 | Diaz et al. | Feb 2004 | A1 |
| 20040059181 | Alferness | Mar 2004 | A1 |
| 20040064014 | Melvin et al. | Apr 2004 | A1 |
| 20040127983 | Mortier et al. | Jul 2004 | A1 |
| 20040133062 | Pai et al. | Jul 2004 | A1 |
| 20040133063 | McCarthy et al. | Jul 2004 | A1 |
| 20040147805 | Lau et al. | Jul 2004 | A1 |
| 20040147965 | Berger | Jul 2004 | A1 |
| 20040167374 | Schweich et al. | Aug 2004 | A1 |
| 20040181118 | Kochamba | Sep 2004 | A1 |
| 20040181120 | Kochamba | Sep 2004 | A1 |
| 20040181124 | Alferness | Sep 2004 | A1 |
| 20040186342 | Vanden Hock et al. | Sep 2004 | A1 |
| 20040210104 | Lau et al. | Oct 2004 | A1 |
| 20040215308 | Bardy et al. | Oct 2004 | A1 |
| 20040225304 | Vidlund et al. | Nov 2004 | A1 |
| 20040243229 | Vidlund et al. | Dec 2004 | A1 |
| 20040249242 | Lau et al. | Dec 2004 | A1 |
| 20040267083 | McCarthy et al. | Dec 2004 | A1 |
| 20040267329 | Raman et al. | Dec 2004 | A1 |
| 20050004428 | Cox et al. | Jan 2005 | A1 |
| 20050010079 | Bertolero et al. | Jan 2005 | A1 |
| 20050014992 | Lilip et al. | Jan 2005 | A1 |
| 20050020874 | Lau et al. | Jan 2005 | A1 |
| 20050033109 | Lau et al. | Feb 2005 | A1 |
| 20050038316 | Taylor | Feb 2005 | A1 |
| 20050054892 | Lau et al. | Mar 2005 | A1 |
| 20050059853 | Kochambe | Mar 2005 | A9 |
| 20050059854 | Hoek et al. | Mar 2005 | A1 |
| 20050059855 | Lau | Mar 2005 | A1 |
| 20050065396 | Mortier et al. | Mar 2005 | A1 |
| 20050075723 | Schroeder et al. | Apr 2005 | A1 |
| 20050085688 | Girard et al. | Apr 2005 | A1 |
| 20050090707 | Lau et al. | Apr 2005 | A1 |
| 20050133941 | Schuhmacher | Jun 2005 | A1 |
| 20050143620 | Mortier et al. | Jun 2005 | A1 |
| 20050148814 | Fischi et al. | Jul 2005 | A1 |
| 20050171589 | Lau et al. | Aug 2005 | A1 |
| 20050192474 | Vanden Hoek et al. | Sep 2005 | A1 |
| 20050197527 | Bolling | Sep 2005 | A1 |
| 20050228217 | Alferness et al. | Oct 2005 | A1 |
| 20050256368 | Klenk et al. | Nov 2005 | A1 |
| 20050283042 | Meyer et al. | Dec 2005 | A1 |
| 20050288715 | Lau et al. | Dec 2005 | A1 |
| 20060004249 | Kute et al. | Jan 2006 | A1 |
| 20060009675 | Meyer | Jan 2006 | A1 |
| 20060009831 | Lau et al. | Jan 2006 | A1 |
| 20060052660 | Chin | Mar 2006 | A1 |
| 20060063970 | Raman et al. | Mar 2006 | A1 |
| 20060155165 | Vanden Hoek et al. | Jul 2006 | A1 |
| 20060229490 | Chin | Oct 2006 | A1 |
| 20060270896 | Dietz et al. | Nov 2006 | A1 |
| 20070032696 | Duong | Feb 2007 | A1 |
| 20070043416 | Callas et al. | Feb 2007 | A1 |
| 20070208211 | Alferness et al. | Sep 2007 | A1 |
| 20070208215 | Hjelle | Sep 2007 | A1 |
| 20070208217 | Walsh et al. | Sep 2007 | A1 |
| 20070219407 | Vanden Hoek et al. | Sep 2007 | A1 |
| 20070225547 | Alferness et al. | Sep 2007 | A1 |
| 20070255093 | Lau et al. | Nov 2007 | A1 |
| 20080033234 | Hjelle | Feb 2008 | A1 |
| 20080064917 | Bar et al. | Mar 2008 | A1 |
| 20090062596 | Leinsing et al. | Mar 2009 | A1 |
| 20090131743 | Hjelle et al. | May 2009 | A1 |
| 20100004504 | Callas | Jan 2010 | A1 |
| 20100094080 | Hjelle et al. | Apr 2010 | A1 |
| 20100160721 | Alferness et al. | Jun 2010 | A1 |
| 20100185050 | Alferness et al. | Jul 2010 | A1 |
| 20100268019 | Hjelle et al. | Oct 2010 | A1 |
| 20110015616 | Straubinger et al. | Jan 2011 | A1 |
| 20120253112 | Hjelle et al. | Oct 2012 | A1 |
| Number | Date | Country |
|---|---|---|
| 324524 | Aug 1920 | DE |
| 3831540 | Apr 1989 | DE |
| 29517393 | Feb 1996 | DE |
| 0280564 | Aug 1988 | EP |
| 0303719 | Feb 1989 | EP |
| 0557964 | Sep 1993 | EP |
| 2209678 | May 1989 | GB |
| 60-203250 | Oct 1985 | JP |
| 01-145066 | Jun 1989 | JP |
| 02-271829 | Nov 1990 | JP |
| 2002-532189 | Oct 2002 | JP |
| 1009457 | Apr 1983 | SU |
| WO 199303685 | Mar 1993 | WO |
| WO 199616601 | Jun 1996 | WO |
| WO 199631175 | Oct 1996 | WO |
| WO 199814136 | Apr 1998 | WO |
| WO 199829041 | Jul 1998 | WO |
| WO 199835632 | Aug 1998 | WO |
| WO 199858598 | Dec 1998 | WO |
| WO 199944534 | Sep 1999 | WO |
| WO 199952470 | Oct 1999 | WO |
| WO 199952471 | Oct 1999 | WO |
| WO 200001306 | Jan 2000 | WO |
| WO 200002500 | Jan 2000 | WO |
| WO 200006026 | Feb 2000 | WO |
| WO 200006027 | Feb 2000 | WO |
| WO 200006028 | Feb 2000 | WO |
| WO 200016700 | Mar 2000 | WO |
| WO 200028912 | May 2000 | WO |
| WO 200028918 | May 2000 | WO |
| WO 0036995 | Jun 2000 | WO |
| WO 200102500 | Jan 2001 | WO |
| WO 200103608 | Jan 2001 | WO |
| WO 200110421 | Feb 2001 | WO |
| WO 200167985 | Sep 2001 | WO |
| WO 200191667 | Dec 2001 | WO |
| WO 200195830 | Dec 2001 | WO |
| WO 200213726 | Feb 2002 | WO |
| WO 2002000099 | Sep 2002 | WO |
| WO 2003022131 | Mar 2003 | WO |
| WO 2006023580 | Mar 2006 | WO |
| WO 2008011411 | Jan 2008 | WO |
| WO 2010111592 | Sep 2010 | WO |
| Entry |
|---|
| U.S. Appl. No. 09/635,345, filed Aug. 2000, Chin. |
| U.S. Appl. No. 14/053,261, filed Oct. 2013, Hjelle et al. |
| U.S. Appl. No. 14/053,587, filed Oct. 2013, Hjelle et al. |
| U.S. Appl. No. 14/053,590, filed Oct. 2013, Hjelle et al. |
| U.S. Appl. No. 29/469,753, filed Oct. 2013, Hjelle et al. |
| U.S. Appl. No. 60/148,130, filed Aug. 1999, Chin. |
| U.S. Appl. No. 60/150,737, filed Aug. 1999, Chin. |
| “Abstracts From the 68th Scientific Sessions, Anaheim Convention Center, Anaheim, California, Nov. 13-16, 1995,” American Heart Association Supplement to Circulation, vol. 92, No. 8, Abstracts 1810-1813 (Oct. 15, 1995). |
| Bolling,et al., “Intermediate-Term Outcome of Mitral Reconstruction in Cardiomyopathy”, J Thorac. Cardiovasc. Surg., Feb. 1998, 115(2):381-388. |
| Bourge, “Clinical Trial Begins for Innovative Device-Altering Left Ventricular Shape in Heart Failure”, UAB Insight, posted Aug. 8, 2012, retrieved Jun. 17, 2004 , http://www.health.uab.edu/show, 2 pages. |
| Capomolla et al., “Dobutamine and nitroprusside infusion in patients with severe congestive heart failure: Hemodynamic improvement by discordant effects on mitral regurgitation, left atrial function, and ventricular function”, American Heart Journal, Dec. 1997, 1089-1098. |
| Capouya et al., “Girdling Effect of Nonstimulated Cardiomyoplasty on Left Ventricular Function”, Ann Thorac. Surg., 1993, 56:867-871 |
| Cohn, “The Management of Chronic Heart Failure”, The New England Journal of Medicine, Aug. 15, 1996, 335(7): 490-498. |
| Coletta et al., “Prognostic value of left ventricular volume response during dobutamine stress echocardiography,” European Heart Journal, Oct. 1997, 18: 1599-1605. |
| Daubeney et al., “Pulmonary Atresia/Intact Ventricular Septum: Early Outcome After Right Ventricular Outflow Reconstruction by Surgery or Catheter Intervention,” Supplement to Circulation, Oct. 15, 1995, 92(8), Abstract 1812. |
| DeVries et al., “A Novel Technique for Measurement of Pericardial Balloon,” Am. J Physiol Heart Circ Physiol, Jan. 2001, 280(6):H2815-H2822. |
| European Search Report in European Application No. 13844676.0, dated Jun. 2, 2016, 8 pages. |
| Extended European Search Report in European Application No. 13845313.9, dated Jun. 1, 2016, 8 pages. |
| Ghanta, et al., “Cardiovascular Surgery: Adjustable, Physiological Ventricular Restraint Improves Left Ventricular Mechanics and Reduces Dilation in an Ovine Model of Chronic Heart Failure,” Circulation, JAHA, 2007, 115: 1201-10. |
| Guasp., “Una protesis contentiva para el tratamiento de la miocardiopatia dilatada,” Revista Espanola de Cardiologia, Jul. 1998, 51(7): 521-528. |
| Hamilton et al., “Static and Dynamic Operating Characteristics of a Pericardial Balloon,” J Appl. Physiol, Apr. 2001, 90(4):1481-1488. |
| Hung, et al., “Persistent Reduction of Ischemic Mitral Regurgitation by Papillary Muscle Repositioning: Structural Stabilization of the Pipillary Muscle Ventricular Wall Complex,” Circulation, JAHA, 2007, 116:1-259 1-263. |
| International Search Report and Written Opinion in International Application No. PCT/US2013/064894, dated Apr. 3, 2014, 27 pages. |
| International Search Report and Written Opinion in International Application No. PCT/US2013/064895, dated Apr. 21, 2014, 14 pages. |
| Justo et al., “Outcomes of Transcatheter Perforation of the Right Ventricular Outflow Tract as Primary Management for Pulmonary Valve Atresia in the Newborn,” Supplement to Circulation, Oct. 15, 1995, 92(8), Abstract 1813. |
| Kass et al., “Reverse Remodeling From Cardiomyoplasty in Human Heart Failure External Constraint Versus Active Assist,” Circulation, May 1, 1995, 91(9):2314-2318, retrieved Jan. 16, 2014, http://circ.ahajournals.org/content/91/9/2314.full. |
| Labrousse, Louis et al., “Implantation of a Cardiac Support Device by the ‘Parachute-Like’ Technique Through Sternal and Trans-Abdominal Approach,” Abstract, 94 Programme of the 4th EACTSIESTS Joint Meeting, Sep. 28, 2005, Barcelona, Spain. |
| Lamas, et al., “Clinical Significance of Mitral Regurgitation After Acute Myocardial Infarction,” Circulation-JAHA, Aug. 5, 1997, 96(3):827-833, retrieved Jan. 16, 2014, http://circ.ahajournals.org/content/96/3/827.long. |
| Lei-Cohen, et al., “Design of a New Surgical Approach for Ventricular Remodeling to Relieve Ischemic Mitral Regurgitation,” Circulation, Jun. 13, 2000, 101:2756-2763. |
| Levin et al., “Reversal of Chronic Ventricular Dilation in Patients with End-Stage Cardiomyopathy by Prolonged Mechanical Unloading,” Circulation, Jun. 1, 1995, 91(11): 2717-2720, retrieved Jan. 16, 2014, http://circ.ahajournals.org/content/91/11/2717.long. |
| Lloyd et al., “The PDA Coil Registry: Report of the First 535 Procedures,” Supplement to Circulation, Oct. 15, 1995, 92(8), Abstract 1811. |
| Oh et al., “The Effects of Prosthetic Cardiac Binding and Adynamic Cardiomyoplasty in a Model of Dilated Cardiomyopathy,” The Journal of Thoracic and Cardiovascular Surgery, Jul. 1998, 116(1):148-153. |
| Pai, et al., “Valvular Egurgitation,” Clinical Science Abstracts, 2000, 1800-1804. |
| Paling, “Two-Bar Fabrics (Part-Set Threading)”, Warp Knitting Technology, Columbine Press (Publishers) Ltd., Buxton, Great Britain, p. III (1970). |
| Timek, et al., “Pathogenesis of Mitral Regurgitation in Tachycardia Induced Cardiomyopathy,” Circulation-JAHA, 2001, 104:1-47-I-53. |
| Vaynblat et al., “Cardiac Binding in Experimental Heart Failure,” Ann. Thorac. Surg., 1994, vol. 64, 11 pages. |
| Vinereanu, et al., “‘Pure’ diastolic dysfunction is associated with long-axis systolic dysfunction. Implications for the diagnosis and classification of heart failure,” European Journal of Heart Failure, Aug. 2005, 7(5): 820-828 (Abstract Only). |
| Number | Date | Country | |
|---|---|---|---|
| 20180368980 A1 | Dec 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61713351 | Oct 2012 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15162029 | May 2016 | US |
| Child | 16118799 | US | |
| Parent | 14053590 | Oct 2013 | US |
| Child | 15162029 | US |
